What is the current stock price of Delcath Systems, Inc. (DCTH)?

As of the latest market data, Delcath Systems, Inc. (DCTH) is trading at $10.04. The stock has seen a gain of 1.62% today.

Does Delcath Systems, Inc. (DCTH) pay a dividend?

Based on current data, Delcath Systems, Inc. does not have a confirmed active dividend policy.

What is the market cap of Delcath Systems, Inc.?

The current market capitalization of Delcath Systems, Inc. (DCTH) is approximately unavailable.

DCTH

Delcath Systems, Inc.·Healthcare

10.04

1.619%(+0.16)

Market Closed

10.79

7.470%(+0.75)

After Hours

Last Updated: — ET

52W L: $8.1252W H: $18.23

DCTH NEWS

businesswire.com

5d ago

Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on liver-directed cancer therapies, today announced that its proprietary CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (M-PHP) has been included as a recommended liver-directed regional therapy option in the newly published Uveal Melanoma: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up (April 2026). M-PHP is also re.

businesswire.com

Apr 1

Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will attend the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting, taking place April 11–15, 2026, in Toronto, Canada. At the event, Delcath's Hepatic Delivery System for use in percutaneous hepatic perfusion will be featured in three presentations. On April 13, 2026, at 2:40 PM ET, Dr. Eric We.

defenseworld.net

Mar 23

Contrasting Delcath Systems (NASDAQ:DCTH) & ADB International Group (OTCMKTS:EQUR)

Delcath Systems (NASDAQ: DCTH - Get Free Report) and ADB International Group (OTCMKTS:EQUR - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends. Profitability This table compares Delcath Systems and

defenseworld.net

Mar 5

Delcath Systems, Inc. (NASDAQ:DCTH) Receives $22.50 Average PT from Analysts

Delcath Systems, Inc. (NASDAQ: DCTH - Get Free Report) has earned an average recommendation of "Moderate Buy" from the six analysts that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average twelve-month target price among

businesswire.com

Mar 3

Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of the full results from the investigator-initiated CHOPIN randomized Phase 2 clinical trial, led by Principal Investigator Professor Ellen Kapiteijn, MD, from Leiden University Medical Center's Department of Medical Oncology. The publication, titled “Percutaneous.

seekingalpha.com

Mar 2

Delcath: Fundamentals Intact, Despite Share Price Weakness

Delcath Systems, Inc.'s revenue remains under pressure due to weak patient starts in the third quarter of 2025. The fundamentals of the company remain intact, though, and 2026 should be another year of strong growth. Delcath's profitability will be under pressure due to investments in clinical trials and sales and marketing.

Company Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Sector

Healthcare

Industry

Medical - Devices

Employees

IPO Date

2018-05-03

Beta

0.43

Websitewww.delcath.com↗